
Diabetic Neuropathic Pain- Pipeline Insight, 2025
Description
DelveInsight’s, “Diabetic Neuropathic Pain- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic Neuropathic Pain: Overview
Diabetic neuropathic pain is a common complication of diabetes mellitus, characterized by chronic, often debilitating pain that affects the peripheral nerves. The signs and symptoms of diabetic neuropathic pain can vary widely, but commonly include tingling, burning, shooting pain, numbness, and hypersensitivity in the affected areas, typically starting in the feet and gradually progressing to involve the hands and other parts of the body. Patients often experience heightened pain at night, which can significantly disrupt sleep and quality of life.
The causes and pathophysiology of diabetic neuropathic pain are multifactorial. Chronic high blood sugar levels in diabetes can lead to nerve damage (neuropathy) through various mechanisms, including inflammation, oxidative stress, and metabolic imbalances. Additionally, vascular complications associated with diabetes can impair blood flow to the nerves, exacerbating nerve damage. Genetic predisposition and lifestyle factors such as smoking and alcohol consumption can also contribute to the development and progression of diabetic neuropathy.
Diagnosis of diabetic neuropathic pain involves a thorough medical history, physical examination, and often nerve conduction studies or electromyography to assess nerve function. Blood tests may be performed to evaluate glucose control and rule out other causes of neuropathy.
Diabetic neuropathic pain treatment aims to alleviate pain, improve nerve function, and manage underlying diabetes. This may involve a combination of medications such as antidepressants, anticonvulsants, and analgesics to manage pain, along with lifestyle modifications such as blood sugar control, regular exercise, and avoiding smoking and excessive alcohol intake. Physical therapy, occupational therapy, and alternative therapies like acupuncture may also be beneficial in managing symptoms and improving quality of life for individuals with diabetic neuropathic pain.
""Diabetic Neuropathic Pain- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Neuropathic Pain Emerging Drugs
Further product details are provided in the report……..
Diabetic Neuropathic Pain: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic Neuropathic Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathic Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathic Pain drugs.
Diabetic Neuropathic Pain Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diabetic Neuropathic Pain: Overview
Diabetic neuropathic pain is a common complication of diabetes mellitus, characterized by chronic, often debilitating pain that affects the peripheral nerves. The signs and symptoms of diabetic neuropathic pain can vary widely, but commonly include tingling, burning, shooting pain, numbness, and hypersensitivity in the affected areas, typically starting in the feet and gradually progressing to involve the hands and other parts of the body. Patients often experience heightened pain at night, which can significantly disrupt sleep and quality of life.
The causes and pathophysiology of diabetic neuropathic pain are multifactorial. Chronic high blood sugar levels in diabetes can lead to nerve damage (neuropathy) through various mechanisms, including inflammation, oxidative stress, and metabolic imbalances. Additionally, vascular complications associated with diabetes can impair blood flow to the nerves, exacerbating nerve damage. Genetic predisposition and lifestyle factors such as smoking and alcohol consumption can also contribute to the development and progression of diabetic neuropathy.
Diagnosis of diabetic neuropathic pain involves a thorough medical history, physical examination, and often nerve conduction studies or electromyography to assess nerve function. Blood tests may be performed to evaluate glucose control and rule out other causes of neuropathy.
Diabetic neuropathic pain treatment aims to alleviate pain, improve nerve function, and manage underlying diabetes. This may involve a combination of medications such as antidepressants, anticonvulsants, and analgesics to manage pain, along with lifestyle modifications such as blood sugar control, regular exercise, and avoiding smoking and excessive alcohol intake. Physical therapy, occupational therapy, and alternative therapies like acupuncture may also be beneficial in managing symptoms and improving quality of life for individuals with diabetic neuropathic pain.
""Diabetic Neuropathic Pain- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathic Pain.
This segment of the Diabetic Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Neuropathic Pain Emerging Drugs
- Cemdomespib: Biogen
- LX9211: Lexicon Pharmaceuticals
- AJH-2947: JMackem
Further product details are provided in the report……..
Diabetic Neuropathic Pain: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Neuropathic Pain
- There are approx. 10+ key companies which are developing the therapies for Diabetic Neuropathic Pain. The companies which have their Diabetic Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II include, Lexicon Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diabetic Neuropathic Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathic Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathic Pain drugs.
Diabetic Neuropathic Pain Report Insights
- Diabetic Neuropathic Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Neuropathic Pain drugs?
- How many Diabetic Neuropathic Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathic Pain?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathic Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Neuropathic Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
- Lexicon Pharmaceuticals
- Biogen
- JMackem
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
- Eli Lilly and Company
- Lateral Pharma Pty Ltd
- Tris Pharma, Inc.
- LX9211
- Cemdomespib
- AJH-2947
- YJ001
- LY3857210
- LAT8881
- GRT6005
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Diabetic Neuropathic Pain: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetic Neuropathic Pain– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- LX9211: Lexicon Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AJH-2947: JMackem
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic Neuropathic Pain Key Companies
- Diabetic Neuropathic Pain Key Products
- Diabetic Neuropathic Pain- Unmet Needs
- Diabetic Neuropathic Pain- Market Drivers and Barriers
- Diabetic Neuropathic Pain- Future Perspectives and Conclusion
- Diabetic Neuropathic Pain Analyst Views
- Diabetic Neuropathic Pain Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.